Navigation Links
Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
Date:1/11/2011

WALTHAM, Mass., Jan. 11, 2011 /PRNewswire/ -- Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC).  The data is being published in the January 15, 2011 issue of Cancer Research.

"These findings demonstrate the promise for epigenetic therapy in cancer management and provide us with important new insights to guide further development of human treatments for lung cancer," said Steven Belinsky, Ph.D., vice president for academic research, director, lung cancer program, Lovelace Respiratory Research Institute.  "Epigenetic therapy may circumvent the problem of tumor heterogeneity by inducing the re-expression of multiple tumor suppressor genes essential for abrogating cancer cell survival and proliferation."

The purpose of the study was to determine the efficacy of a demethylating agent, Vidaza, alone or in combination with a histone deacetylase inhibitor (HDACi), entinostat, on the growth of tumors engrafted in the lungs of the nude rat and on reprogramming of the epigenome.  Researchers developed an orthotopic lung cancer model in which xenografts of human lung cancer-derived cell lines are efficiently engrafted throughout the lungs of the nude rat.  The study showed that combining the HDACi entinostat with the demethylating agent Vidaza profoundly affected growth of K-ras/p53 mutant lung adenocarcinomas engrafted orthotopically in immunocompromised nude rats by targeting and ablating pleomorphic cells that occupied up to 75% of the tumor masses.

"These exciting findings of entinostat combined with Vidaza in a validated animal model of lung cancer support ongoing clinical efforts with epigenetic therapy in solid tumors and provide a foundation for identification and  developm
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
2. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
3. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
4. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
5. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
6. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
7. Amarin Announces Successful Completion of Offering of American Depositary Shares
8. Celleration, Inc. Announces Close of $8 Million Series E Financing
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
11. Dehaier Medical Announces Participation in Arab Health 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ( ... "North America Open System MRI Market - Growth, Trends ... offering. The key players in the industry ... Siemens Healthcare and Toshiba Medical Systems ... replacing CT because of its higher sensitivity and use ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cardiovascular ... to their offering. Drug delivery to ... other systems because of the anatomy and physiology ... nutrients to all organs of the body. Drugs ...
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
Breaking Medicine Technology:North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3LifeNet Health to add more than 160 jobs in 2015 2
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... today that it has commenced vaccination of,volunteers for ... pandemic,influenza H5N1 vaccine. The Phase II clinical trial ... and efficacy of the pandemic,influenza H5N1 vaccine. The ...
... 11 ImClone Systems,Incorporated (Nasdaq: IMCL ... BMY ),today announced that a Phase III ... chemotherapy (vinorelbine plus cisplatin),met its primary endpoint ... in patients with advanced non-small cell lung ...
Cached Medicine Technology:Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 3ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 4ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 5ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 6ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 7ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 8ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 9
(Date:5/30/2015)... 2015 On Sunday, June 14, 2015, ... – Jefferson Health will host Journey to Survivorship, a ... speaker, brunch and resources for cancer survivors and their ... the event will be Kathy LaTour, editor-at-large for Cure ... then again in 2007, LaTour provides a unique perspective ...
(Date:5/30/2015)... Chicago, Il (PRWEB) May 30, 2015 ... for Clinical Oncology (ASCO) Annual Meeting 2015 show activity ... cancer, in one case specifically against brain metastases and ... HER2+ breast cancer patients. , "I am thrilled to ... patient in her early 40s. She didn't have any ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
(Date:5/30/2015)... 2015 San Luis Obispo insurance ... offering a free analysis and consultation for anyone interested ... Disability Awareness Month, which was created by the non-profit ... United States such as Polk recognize the proclamation, and ... the possibility of disability, as well as the often-overlooked ...
Breaking Medicine News(10 mins):Health News:Abington Hospital to Host Cancer Survivorship Event 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... efforts,to mobilize opposition to the Bush Administration,s planned $770 ... benefits in the,year ahead, the Coalition to Protect Senior ... to go on record publicly opposing,cuts to seniors, Medicare ... an especially negative impact on rural America,s nursing home,care., ...
... KALAMAZOO, Mich., May 28 Stryker Corporation,(NYSE: SYK ... following,investor conferences:, June 11, 2008 - 9:00 ... LLC Biotechnology and Medical Technology Conference New ... a.m. Pacific Time Goldman Sachs Twenty-Ninth Annual Global ...
... experts don,t endorse use of the drugs to combat ... painkillers called non-steroidal anti-inflammatory drugs (NSAIDs) appear to reduce ... medication in the class works better than the others, ... the largest of its kind, contradicts some previous studies ...
... -- WASHINGTON, DC) The American College of ... announced today a multi-year partnership to jointly sponsor ... Fla., March 2831, 2009, during ACC.09, the ACCs ... cardiovascular meeting. This will be the beginning ...
... FDA,s Janet Woodcock, MD, Provides,Practical Guidance on New ... that the Food and,Drug Administration (FDA) has new ... manufacturers can be required to develop,comprehensive risk assessment ... To help pharmaceutical companies, consultants and other drug ...
... Health Care Association: Rising Energy and Food Costs, Existing,Medicaid ... Texas, May 28 A new national study,analyzing how ... rural America,s seniors and nursing homes finds Texas will ... Texas Health Care,Association (THCA) to warn that yet another ...
Cached Medicine News:Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 2Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 3Health News:Stryker to Present at Investor Conferences 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 3Health News:ACC and CRF announce partnership on ACC's Innovation in Intervention: i2 Summit 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 3
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Multi-curved shafts with straight blades and longitudinal serrations. Slide lock and serrated handle with polished finish. Blade length: 27 mm....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. Straight shafts. Cross action. Round handle....
Medicine Products: